Telo Genomics Cash Flow From Operations vs. Cash And Equivalents

TELO Stock  CAD 0.12  0.01  9.09%   
Based on Telo Genomics' profitability indicators, Telo Genomics Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Telo Genomics' ability to earn profits and add value for shareholders. At this time, Telo Genomics' Graham Number is fairly stable compared to the past year. Shareholders Equity Per Share is likely to climb to 0.13 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (0.12).
For Telo Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telo Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telo Genomics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telo Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telo Genomics Corp over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Telo Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telo Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telo Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Telo Genomics Corp Cash And Equivalents vs. Cash Flow From Operations Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth.
JavaScript chart by amCharts 3.21.15RPNBVAHEMTDSGFTELO 01M2M3M4M5M -3M-2.5M-2M-1.5M-1M-500K0
Telo Genomics Corp is rated fifth in cash flow from operations category among its peers. It also is rated fifth in cash and equivalents category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.

Telo Cash And Equivalents vs. Cash Flow From Operations

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Telo Genomics

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(2.63 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Telo Genomics

Cash

 = 

Bank Deposits

+

Liquidities

 = 
24.25 K
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Telo Cash And Equivalents Comparison

Telo Genomics is currently under evaluation in cash and equivalents category among its peers.

Telo Genomics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Telo Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telo Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Telo Genomics' change in net profit over the period of time. It can combine multiple indicators of Telo Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income37.8 K64.2 K
Operating Income-2.5 M-2.7 M
Income Before Tax-2.5 M-2.7 M
Total Other Income Expense Net-6 K-6.3 K
Net Loss-2.5 M-2.7 M
Income Tax Expense-4.7 K-4.4 K
Net Loss-3.2 M-3.4 M
Net Loss-2.4 M-2.5 M
Change To Netincome136.3 K129.5 K
Net Loss(0.04)(0.02)
Income Quality 0.91  1.12 

Telo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Telo Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telo Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telo Genomics' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Telo Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Analyzer Now

   

Portfolio Analyzer

Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
All  Next Launch Module

Use Investing Themes to Complement your Telo Genomics position

In addition to having Telo Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Biotech Thematic Idea Now

Biotech
Biotech Theme
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Telo Stock Analysis

When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.